MCM
CARM

Murphy Capital Management’s Carisma Therapeutics CARM Stock Holding History

Murphy Capital Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-955
Closed -$53K – 274
2016
Q3 		$53K Buy
+955
New +$71.1K 0.01% 286

Other funds holding CARM

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Murphy Capital Management's CARM Position: Q4 2016 in Review

Murphy Capital Management sold out of Carisma Therapeutics (CARM) in Q4 2016, closing a stake of 955 shares — an estimated $53K sold.

Murphy Capital Management first reported a position in CARM in Q3 2016 and held it in 1 quarter. The position peaked at $53K in Q3 2016. 27 funds tracked by Wall St. Rank hold CARM as of Q4 2016.

  • Murphy Capital Management reported no remaining Carisma Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Murphy Capital Management sold 955 Carisma Therapeutics shares in Q4 2016, an estimated $53K.
  • Murphy Capital Management first reported a position in Carisma Therapeutics in Q3 2016 and held it in 1 quarter.
  • Murphy Capital Management's Carisma Therapeutics position peaked at $53K in Q3 2016.
  • 27 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2016.

Based on Murphy Capital Management's 13F filing for Q4 2016, filed 31 Jan 2017.